Inhalation and Inhalers Gaining Ground in Drug Delivery Greystone Associates Survey Finds Evolving Device Technologies Creating New Opportunities for Drug Developers
May 25, 2007 (PRLEAP.COM) Health News(Amherst, NH) – Greystone Associates, a leading pharmaceutical technology consulting firm, has completed a comprehensive analysis of the inhaled drug delivery sector. The analysis includes comprehensive assessments of inhalation product candidates, profiles of inhalation market participants, industry data and forecasts, and detailed analysis of design and economic factors.
At a time when the drug industry is striving for patient-friendly delivery methods for new and existing drugs, the growing availability of innovative inhaler device designs is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. The rising potential of dry powder inhalation is being driven by escalating research activity in powder formulations, advances in particle engineering, and the development of novel device architectures. In a similar fashion, the metered dose inhaler (MDI) has gone through a re-birth of sorts over the last five years, as regulatory requirements and efficacy issues related to variability in patient use of MDIs have fostered design changes at both the drug and device level.
Greystone Associates, a leading pharmaceutical technology consulting firm, has completed a comprehensive analysis of the inhaled drug delivery sector. Several of these emerging combination drug products will have a significant impact in the therapeutic markets they target, improving patient compliance and effectively changing the way important illnesses and conditions are treated. For inhalation device suppliers and their drug partners, understanding the concerns, preferences, and limitations of consumers to self-medicate via inhalation will be the driving force for future–generation inhaled drugs and spell the difference between successful ventures in this market and entities that will fail to prosper in spite of highly favorable market dynamics.
The market for inhaled drug delivery will remain a dynamic one, as business factors related to direct-to-consumer marketing, patent expiry-driven generic competition and the changing regulatory climate create new risks and opportunities. These findings are contained in a new and comprehensive repor, researched and written by Greystone Delivering Drugs by Inhalation: Emerging Therapeutic Opportunities includes comprehensive assessments of inhalation product candidates, profiles of inhalation market participants, industry data and forecasts, and detailed analysis of design and economic factors.
More information is available at www.greystoneassociates.org .
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Source: Greystone Associates